Company intelligence / Profile preview
Genecombio
Shanghai, Shanghai Shi, Chinagenecombio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Genecombio Ltd. is a private biotechnology company founded in 2021 and headquartered in Shanghai, China. The company specializes in AAV-based gene therapies targeting rare neurological disorders such as Rett syndrome and spinal muscular atrophy type 2. Its lead programs include GCB‑001 and GCB‑002, both of which are advancing through early clinical development. The company's technology platform centers on adeno-associated virus vectors for targeted delivery of therapeutic genes such as MECP2.
- Therapeutic areas
- Neurology
- Modalities
- AAV based gene therapyBiological products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major partnerships disclosed; likely operates independently or with academic/clinical collaborators typical for early-stage biotech companies.
Beyond the preview
Go deeper on Genecombio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genecombio.